ストックスクリーナーアプリを入手
5.43
1.45%
-0.08
アフターアワーズ：
5.57
0.14
+2.58%
前日終値:
$5.51
開ける：
$5.56
24時間の取引高:
3.79M
Relative Volume:
2.23
時価総額：
$1.11B
収益：
-
当期純損益:
$-129.48M
株価収益率:
-9.7242
EPS:
-0.5584
ネットキャッシュフロー:
$-106.97M
1週間 パフォーマンス:
-1.09%
1か月 パフォーマンス:
-7.97%
6か月 パフォーマンス:
-7.18%
1年 パフォーマンス:
+110.47%
1日の値動き範囲:
$5.43
$5.68
1週間の範囲:
$5.43
$6.025
52週間の値動き範囲:
$2.43
$7.005
Savara Inc Stock (SVRA) Company Profile
Compare SVRA vs VRTX, REGN, ARGX, RVMD, ALNY
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SVRA
Savara Inc
|
5.43 | 1.13B | 0 | -129.48M | -106.97M | -0.5584 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Savara Inc Stock (SVRA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-24 | 再開されました | Oppenheimer | Outperform |
| 2025-10-20 | 開始されました | Wells Fargo | Overweight |
| 2025-08-15 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2025-05-29 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2024-12-20 | 開始されました | Wells Fargo | Overweight |
| 2024-11-13 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2024-02-15 | 開始されました | JMP Securities | Mkt Outperform |
| 2023-11-07 | 開始されました | Guggenheim | Buy |
| 2023-05-16 | アップグレード | Jefferies | Hold → Buy |
| 2023-03-31 | ダウングレード | Jefferies | Buy → Hold |
| 2021-03-16 | 開始されました | Piper Sandler | Overweight |
| 2021-03-15 | 開始されました | Oppenheimer | Outperform |
| 2019-06-13 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-06-13 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-06-13 | ダウングレード | Ladenburg Thalmann | Buy → Neutral |
| 2018-08-13 | 再開されました | ROTH Capital | Neutral |
| 2018-01-03 | 開始されました | Ladenburg Thalmann | Buy |
| 2017-09-27 | 再開されました | ROTH Capital | Buy |
| 2017-09-22 | 開始されました | Jefferies | Buy |
| 2017-09-11 | 開始されました | JMP Securities | Mkt Outperform |
すべてを表示
Savara Inc (SVRA) 最新ニュース
Savara Inc (SVRA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Savara Inc (SVRA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Savara Inc (SVRA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Savara Inc (SVRA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Savara, Inc. Revenue Breakdown – NASDAQ:SVRA - TradingView
TradingKey - TradingKey
SVRA|Savara Inc|Price:5.510|Chg%:-0.240 - TradingKey
Savara Inc. CFO Robert Lutz Secures 70,000 Stock Options and 35,000 RSUs in Insider Transaction - Kalkine Media
Form 4 Savara Inc For: 24 July By Investing.com - Investing.com South Africa
Savara Inc (NASDAQ: SVRA) grants CFO 70,000 options, 35,000 RSUs - Stock Titan
Savara Inc. (SVRA) Edges Lower as Stock Approaches Critical Support at $5.37Demand Zone - dars.gov.et
ETFs Investing in Savara, Inc. Stocks - TradingView
Savara stock gains as Phase 3 data support FDA review of inhaled lung therapy - Ad-hoc-news.de
If You Invested $1,000 in Savara Inc (SVRA) - Stock Titan
Piper Sandler Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $16 - Moomoo
Here's Why You Should Add Savara Stock to Your Portfolio Now - Yahoo Finance
What Does the FDA's Priority Review Mean for Savara's MOLBREEVI - Kavout | AI
SVRA Q1 2026 Earnings: EPS Misses Estimates Amid Pre-Revenue StageEarnings Revision Upgrade - dars.gov.et
Join Class Action to Recover Losses from Savara Inc. (SVRA)Contact Levi & Korsinsky Before November 7, 2025 - The National Law Review
Savara Announces Participation in the 2026 Jefferies Global Healthcare Conference - AOL.com
Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 20 - AOL.com
Savara stock. Thin-source profile holds the focus. - ad-hoc-news.de
SVRA Q1 2026 Earnings: EPS Misses Estimates as Pre-Commercial Spending RampsOne-Time Gain Impact - dars.gov.et
Enterprise value to EBIT forward of Savara, Inc. – NASDAQ:SVRA - TradingView
Enterprise value to EBITDA forward of Savara, Inc. – NASDAQ:SVRA - TradingView
Price to earnings forward of Savara, Inc. – NASDAQ:SVRA - TradingView
Savara Inc focuses on respiratory drug development as investors watch clinical progress - Ad-hoc-news.de
Price to sales forward of Savara, Inc. – NASDAQ:SVRA - TradingView
Enterprise value to revenue forward of Savara, Inc. – NASDAQ:SVRA - TradingView
Savara Inc. (SVRA) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of November 7, 2025 Deadline - The National Law Review
SVRA Q1 2026 Earnings: EPS Misses Estimates as Clinical Development AdvancesGrowth Acceleration Report - dars.gov.et
Securities Lawsuit Alert: Savara Inc. (SVRA) InvestorsContact Levi & Korsinsky Before November 7, 2025 - The National Law Review
Class Action Lawsuit Alert: Levi & Korsinsky Reminds Savara Inc. (SVRA) Investors of November 7, 2025 Deadline - The National Law Review
SVRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
Levi & Korsinsky Notifies Savara Inc. (SVRA) InvestorsLead Plaintiff Deadline on November 7, 2025 - The National Law Review
Investors SueWallSt as Savara Inc. Faces Securities Fraud Allegations - The National Law Review
Investors in Savara Inc. (SVRA): Protect Your RightsContact Levi & Korsinsky Before November 7, 2025 - The National Law Review
What Savara Investors Should Know About This 580,187-Option Exercise and FDA Timeline - AOL.com
Savara, Inc. Actuals & Estimates (FWB:YB4P) - TradingView
SVRA Forecast — Price Target — Prediction for 2027 - TradingView
Savara, Inc. Actuals & Estimates (SWB:YB4P) - TradingView
YB4P Forecast — Price Target — Prediction for 2027 - TradingView
Savara CFO David Lowrance sells $2.24m in company stock By Investing.com - Investing.com Nigeria
Savara CFO David Lowrance sells $2.24m in company stock - Investing.com UK
Form 4 Savara Inc For: 22 June By Investing.com - Investing.com Nigeria
Savara (SVRA) CFO exercises 580K options and sells 394K shares in Form 4 - Stock Titan
Form 144 Savara Inc For: 22 June By Investing.com - Investing.com South Africa
Form 144 Savara Inc For: 22 June - Investing.com India
[144] Savara Inc SEC Filing - Stock Titan
Savara Inc (SVRA) 財務データ
収益
当期純利益
現金流量
EPS
1.97%
0.83%
大文字化:
|
ボリューム (24 時間):